Nancy E. Kemeny, MD
Professor of Medicine
Memorial Sloan-Kettering Cancer Center
Weill Cornell Medical College of Cornell University
Gastrointestinal Solid Tumor Service
Department of Medicine
New York, NY
AMA PRA Category 1 Credit™ Medium
Mobile + Online on QuantiaMD
Colorectal cancer is the third most common cause of death from cancer in the United States, leading to more than 50,000 deaths annually. Most colorectal cancer cases are diagnosed at an advanced stage in which cancer has spread to nearby lymph nodes or organs, leading to poor overall survival.
Better understanding of molecular pathways has led to the identification of markers that aid in monitoring response to some of the targeted agents. Insights into mutations and deregulated signaling pathways in colorectal cancer have improved the understanding of the heterogeneity of colorectal cancer. Clinical advances have led to better patient outcomes, including the potential for long-term survival in some patients. However, the availability of multiple treatment options adds to the complexity of developing optimal treatment approaches for each individual patient.
Significant opportunities for a multidisciplinary care team to improve patient care exist. These teams must learn to appropriately employ adjuvant therapy for patients with high risk stage II or stage III colorectal cancer and to optimally manage and monitor patients with metastatic colorectal cancer. The goal of this continuing medical education activity is to optimize outcomes in patients with colorectal cancer by improving multidisciplinary approaches to colorectal cancer management.
. Target Audience
This educational activity is designed to meet the needs of oncologists and those who manage patients with cancer.
Upon completion of this educational activity, the participant should be able to:
Incorporate combination therapy and targeted therapies into the treatment of patients with metastatic colorectal cancer.
Outline opportunities for the multidisciplinary oncology team to improve outcomes in patients with metastatic colorectal cancer.
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity.
Dr. Kemeny discloses the following:
Research support: Amgen Inc.
Office of CME:
Zalman S. Agus, MD has no relevant financial relationships to disclose.
Mila Kostic has no relevant financial relationships to disclose.
Medical Communications Media, Inc.:
Sara Thier, PhD, MPH has no relevant financial relationships to disclose.
Elizabeth Paczolt, MD has no relevant financial relationships to disclose.
Investigational and/or Off-Label Use of Commercial Products and Devices:
The Perelman School of Medicine at the University of Pennsylvania requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications. In this educational activity, the faculty discusses the use of new agents including antibodies to VEGF and EGFR to treat metastatic colorectal carcinoma. There is also a discussion about downstaging unresectable liver metastases so they can become resectable.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Perelman School of Medicine at the University of Pennsylvania and Medical Communications Media, Inc. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.
The Perelman School of Medicine at the University of Pennsylvania designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release date: December 23, 2011
Last review date: December 23, 2011
Expiration date: December 22, 2012 Commercial Support Statements
Supported by educational grants from Genentech BioOncology, sanofi-aventis U.S. and Regeneron Pharmaceuticals.
* Link to and Log into program on QuantiaMD.com
* Take the pre-test
* Review the activity
* Take the post-test and score 100%
* You are allowed two retakes
* Complete the evaluation
* View, print, or save a CME certificate verifying your
credit/participation in this activity
There is no charge for CME credit.
© 2011, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher,the Perelman School of Medicine at the University of Pennsylvania, Genentech BioOncology, sanofi-aventis U.S., or Regeneron Pharmaceuticals. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.